TY - JOUR T1 - Impact of Acridine Orange in Patients With Soft Tissue Sarcoma Treated With Marginal Resection JF - Anticancer Research JO - Anticancer Res SP - 6365 LP - 6372 DO - 10.21873/anticanres.13849 VL - 39 IS - 11 AU - HIROYUKI TSUCHIE AU - MAKOTO EMORI AU - NAOHISA MIYAKOSHI AU - HIROYUKI NAGASAWA AU - KYOJI OKADA AU - YASUTAKA MURAHASHI AU - EMI MIZUSHIMA AU - JUNYA SHIMIZU AU - TOSHIHIKO YAMASHITA AU - YOICHI SHIMADA Y1 - 2019/11/01 UR - http://ar.iiarjournals.org/content/39/11/6365.abstract N2 - Background/Aim: Although few studies have shown the effectiveness of adjuvant therapy with acridine orange (AO) for soft tissue sarcoma (STS) patients, no study has investigated this among cases with marginal resection. The aim of the study was to evaluate the effectiveness of AO therapy directly by comparing it to marginal resection cases that did not receive AO. Patients and Methods: This retrospective study included 19 and 33 patients with STS who received AO therapy (AO group) and marginal resection without AO therapy (non-AO group), respectively. The patients' clinical information was collected, and the clinical courses were compared. Results: The local recurrence rate in the AO group was significantly lower than that in the non-AO group (p<0.05). The local recurrence-free survival curves significantly differed between the two groups (p<0.05). High grade malignancy and no treatment with AO were identified as risk factors for local recurrence (p<0.05). Conclusion: AO therapy strongly suppressed local recurrence after marginal resection of STS. ER -